You are here

Home » Content

EPİTELYAL OVER TÜMÖRLERİ İLE bcl-2, nm 23 ve c-erbB-2 EKSPRESYONLARI ARASINDAKİ İLİŞKİ

Journal Name:

  • Cerrahpaşa Tıp Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Ovarian cancer is the most common cause of death among all gynecologic malignancies. Genetic alterations important in ovarian tumorigenesis have been identified recently. Ovarian tumors are the end result of a complex pathway involving multiple oncogenes and tumor suppressor genes. The aim of this study was to investigate the value of nm 23, bcl-2 and c-erbB-2 expressions in epithelial ovarian tumors. We studied 102 patients with benign, borderline and malignant epithelial ovarian tumor. Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded specimens. The expression of nm 23, bcl-2 and c-erbB-2 gene products were investigated immunohistochemically in ovarian carcinomas, borderline and malignant neoplasms. Results.- Significantly more immunoreactivity with bcl-2 protein was present in benign tumors compared to borderline and malignant tumors (p<0.05). bcl-2 expression rate of benign tumors was 97% versus 30% for malignant tumors. In addition; the expression of bcl-2 was lower in mucinous tumors compared to the other types. However, the expression of nm 23 and c-erbB-2 were higher in the borderline and the malignant tumors than in the benign tumors. Also more advanced ovarian carcinomas expressed significantly high levels of c-erbB-2 when compared to the other malignant tumors. There was no correlation between metastatic status of ovarian carcinoma and nm 23 expressions. Conclusion.- The results suggest that expression of nm 23 and c-erbB-2 are important in ovarian carcinogenesis and tumor progression. In addition; this study indicates an inhibitory role of bcl-2 in development and progression of ovarian tumors.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Over kanseri tüm jinekolojik maligniteler arasında en sık ölüme neden olan kanserlerdir. Over tümörleri; çok sayıda onkogen ve tümör supressör genin yer aldığı bir dizi kompleks olayların sonucunda oluşur. Yakın zamanlarda, over tümör gelişiminde rol oynayan çeşitli genetik değişiklikler ortaya konmuştur. Bu çalışmada; benign, borderline ve malign epitelyal over tümörüne ait, 102 formalin fikse ve parafin gömülü materyalde; immunhistokimyasal olarak “nm 23”, “bcl-2” ve “c-erbB- 2” ekspresyonu değerlendirildi. Bulgular: Borderline ve malign tümörlerle karşılaştırıldığında; benign tümörlerdeki “bcl- 2” immunreaktivitesinin belirgin olarak yüksek olduğu saptandı. (p<0.05) Benign tümörlerin %97’sinde “bcl-2” ekspresyonu görülürken, bu oran malign tümörlerde %30 olarak bulundu. Ayrıca; müsinöz tümörlerdeki “bcl-2” ekspresyonunun diğer tümör tiplerine göre daha düşük olduğu gözlendi. Bununla birlikte “nm 23” ve “c-erbB-2” ekspresyonu ise; borderline ve malign tümörlerde benign tümörlere göre daha fazla olarak değerlendirildi. Ancak; metastazı olan ve olmayan olgularda “nm 23” ekpresyonu yönünden istatistiksel olarak anlamlı bir farklılık görülmedi. Sonuç: Bu çalışmanın sonuçları; “nm 23” ve “c-erbB-2” ekpresyonunun, overlerde karsinom gelişimi ve progresyonla ilişkili olduğunu desteklemektedir. “bcl-2” ekspresyonu ise; malignite gelişimi ile ters korelasyon göstermiştir ve “bcl-2” nin malignite gelişminde inhibitör rol oynadığı düşünülmüştür.
FULL TEXT (PDF): 
PDF icon arastirmax-epitelyal-over-tumorleri-ile-bcl-2-nm-23-c-erbb-2-ekspresyonlari-arasindaki-iliski.pdf
  • 2
79-85
  • Turkish

REFERENCES

References: 

1. Massi D, Susini T, Savino L et al. Epithelial ovarian
tumors in the reproductive age group. Cancer 1996; 77:
1131-1136.
2. Chan WY, Cheung KK, Schorge JO et al. Bcl-2 and p53
protein expression, apoptosis and p53 mutation in human
epithelial ovarian cancers. Am J Pathol 2000; 156: 409-
417.
3. Marks JR, Davidoff AM, Kerns B et al. Overexpression
and mutation of p53 in epithelial ovarian cancer. Cancer
Res 1991; 51: 2979-2984.
4. Mandai M, Konishi İ, Koshiyama M, Mori T, Arao S,
Tashiro H, Okamura H, Nomura H, Hiai H, Fukumoto M.
Expression of metastasis-related nm23-H1 and nm23-H2
genes in ovarian carcinomas: Correlation with
clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes
and sex steroid receptor expression. Cancer Res 1994;
54:1825-1830.
5. Harlozinska A, Bar JK, Sobanska E, Goluda M. p53, cerbB-
2 and p21ras expression in tumor effusion cells of
patients with histopathologically different ovarian
neoplasms. Anticancer Res 1997; 17: 3545-3552.
6. Fajac A, Benard J, Lhomme C, Rey A, Duvillard P,
Rochard F, Bernaudin JF, Riou G. c-erbB2 gene
amplification and protein expression in ovarian epithelial
tumors: evaluation of their respective prognostic
significance by multivariate analysis. Int J Cancer 1995;
64: 146-1451.
7. Bosari S, Moneghini L, Graziani D, Lee AKC, Murray JJ,
Coggi G, Viale G. bcl-2 oncoprotein in colorectal
hyperplastic polyps, adenomas and adenocarcinomas.
Hom Pathol 1995; 26: 534-550.
8. Lauwers GY, Scott GV, Korpeh MS.
Immunohistochemical evaluation of bcl-2 protein
expression in gastric adenocarcinomas. Cancer 1995; 75:
2209-2213.
9. Fisman JR,Gumerlock PH, Meyers FJ, White RWD.
Quantation of nm 23 expression in human prostate
tissues. J urol 1994; 152: 202-207.
10. Rosai J. Ackerman’s Surgical Pathology. Ed. Rosai J. 8th
edition. St. Louis, Mosby, 1996; 1461-1539.
11. Igawa M, Rukstalis DB, Tanabe T, Chodok GW. High
levels of nm 23 expressions are related to cell
proliferation in human prostate cancer. Cancer Res 1994;
54: 1313-1318.
12. Bigsby R, Aixin L, Bomalaski J, Stehman FB et al.
Immunohistochemical study of Her 2/neu, Epidermal
Growth factor receptor and steroid receptor expression in
normal and malignant endometrium. Obstet Gynecol
1992; 79: 95-100.
13. Nakamura T, Nomura S, Sakai T, Nariya S. Expression
of bcl-2 oncoprotein in gastrointestinal and uterine
carcinomas and their premalignant lesions. Hum Pathol
1997; 28: 309-315.
14. Ben-Hur H, Gurevich P, Huszar M, Ben-Arie A, Berman
V, Tendler Y, Tchanishev R, Zinder O, Mor G, Zaltsman
Y, Kohen F, Zusman I. Apoptosis and apoptosis-related
proteins in the epithelium of human ovarian tumors:
immunohistochemical and morphometric studies. Eur J
Gynaecol Oncol 1999; 20: 249-253.
15. Henriksen R, Wilander E, Oberg K. Expression and
prognostic significance of bcl-2 in ovarian tumors. Br J
Cancer 1995; 72: 1324-1329.
16. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM.
Down-regulation of bcl-2 by p53 in breast cancer cells.
Cancer Res 1994; 54: 2095-2097.
17. Herod JO, Eliopoulos AG, Warwick J, Niedobitek G,
Young LS, Kerr DJ. The prognostic significance of bcl-2
and p53 expession in ovarian carcinoma. Cancer Res
1996; 56: 2178-2184.
18. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K,
Scmidt M, Lohrs Ul. Bcl-2 expression, p53 accumulation,
and apoptosis in ovarian carcinomas. Am J Clin Pathol
1996; 105: 341-349.
19. Athanassiadou P, Petrakakou E, Sakelariou V, Zerva C,
Liossi A, Michalas S, athanassiades P. Expression of p53,
bcl-2 and heat shock protein (hsp72) in malignant and
benign ovarian tumors. Eur J Cacer Prev 1998; 7: 225-
231.
20. Baba H, Urano T, Okada K, Furukawa K, Nakayama E,
Tanaka H, Iwasaki K, Shiku K. Two isotypes of of
murine nm 23/Nucleoside Diphosphate Kinase, nm 23-
M1 and nm 23-M2 are involved in metastatic suppression
of a murine melanoma line. Cancer Res 1995; 55: 1977-
1981.
21. Schneider J, Romero H, Ruiz R, Centeno MM,
Rodriguez-Escudero FJ. nm 23 expression in advanced
and boredrline ovarian carcinoma. Anticancer Res 1996;
16: 1197-1202.
22. Scambia G, Ferrandina G, Marone M, Panici PB,
Giannitelli C, Piantelli M, Leone A, Mancuso S. nm 23 in
ovarian cancer: correlation with clinical outcome and
other clinicopathologic and biochemical prognostic
parameters. J Clin Oncol 1996; 14: 334-342.
23. Harlozinska A, bar JK, Gerber J. nm 23 expression in
tissue sections and tumor effusion cells of ovarian
neoplasms. Int J Cancer 1996; 69: 415-419.
24. Viel A, Dall’Agnese L, Canzonieri V, Sopracodevole F,
Capozzi E, Carbone A, Visenrin MC, Boiocchi M.
Suppressive Role of the metastasis-related nm 23-H1
gene in human ovarian carcinomas: Association of high
messenger RNA expression with lack of lymph node
metastasis. Cancer Res 1995; 55: 2645-2650.
25. Srivatsa PJ, Cliby WA, Keeney GL, Dodson Mk, Suman
VJ, Roche PC, Podratz KC. Elevated nm 23 protein
expression is correlated with diminished progression-free
survival in patients with epithelial ovarian carcinoma.
Gynecol Oncol 1996; 60: 363-372.
26. Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R,
Arand M, Knapstein PG, Becker R, Oesch F, Tanner B.
Contrubution of c-erbB-2 and topoisomerase Iıalpha to
chemoresistance in ovarian cancer. Cancer Res 1999; 59:
3206-3214.
27. Tanner B, Kreutz E, Weikel W, Meinert R, Oesch F,
Knapstein PG, Becker R. Prognostic significance of cerbB-
2 mRNA in ovarian carcinoma. Gynecol Oncol
1996; 62: 268-277.
28. Matias-Guiu X, Prat J. Molecular pathology of ovarian
carcinomas. Virchows Arch 1998; 433: 103-111.
29. Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B,
Isaia E, Arisio R, Giardina G, Sismondi P. Concurrent
abnormal expression of erbB-2, myc and ras genes is
associated with poor outcome of ovarian cancer patients.
Anticancer Res 1995; 15: 1501-1510.
30. Villa A, Parazzini F, Acerboni S, Guarnerio P, Bolis G.
Survival and prognostic factors of early ovarian cancer.
Br J Cancer 1998; 75: 663-670.

Thank you for copying data from http://www.arastirmax.com